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Background: Growing evidence indicates that miR-200c is involved in carcinogenesis and tumor progression in
non-small-cell lung cancer (NSCLC). However, its precise biological role remains largely elusive.
Methods: The functions of miR-200c and USP25 in migration/invasion and lung metastasis formation were
determined by transwell and tail vein injection assays, respectively. The potential regulatory targets of miR-200c
were determined by prediction tools, correlation with target protein expression, and luciferase reporter assay. The
mRNA expression levels of miR-200c and USP25 were examined in NSCLC cell lines and patient specimens using
quantitative reverse transcription-PCR. The protein expression levels of USP25 were examined in NSCLC cell lines
and patient specimens using western blot and immunohistochemical staining.
Results: We demonstrated that over-expression of miR-200c inhibited NSCLC cells migration, invasion,
epithelial-mesenchymal transition (EMT) in vitro and lung metastasis formation in vivo. Further studies revealed that
USP25 was a downstream target of miR-200c in NSCLC cells as miR-200c bound directly to the 3’-untranslated
region of USP25, thus reducing both the messenger RNA and protein levels of USP25. Silencing of the USP25 gene
recapitulated the effects of miR-200c over-expression. Clinical analysis indicated that miR-200c was negatively
correlated with clinical stage, lymph node metastasis in NSCLC patients. Moreover, USP25 protein and mRNA level
expressions were higher in NSCLC patients, compared to healthy control, and correlated with clinical stage and
lymphatic node metastasis.
Conclusions: These findings indicate that miR-200c exerts tumor-suppressive effects for NSCLC through the
suppression of USP25 expression and suggests a new therapeutic application of miR-200c in the treatment of NSCLC.
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The leading cause of cancer mortality is lung cancer in
the worldwide. Non–small cell lung cancer (NSCLC) is
the most common type of lung cancer, accounting for
more than 85% of all lung cancer cases [1]. Despite the
enormous improvements made in chemotherapy and radio-
therapy over the past few decades, the outlook for patients
with NSCLC was dismal, with only slightly more than 15%* Correspondence: myao@shsci.org
†Equal contributors
1State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer
Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine,
200032 Shanghai, China
Full list of author information is available at the end of the article
© 2014 Li et al.; licensee BioMed Central Ltd. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.of patients alive 5 years after diagnosis. NSCLC can be
further classified into adenocarcinomas, carcinoma, large
cell carcinoma and bronchoalveolar carcinomas (BAC)
[2]. The distant metastases are responsible for the fail-
ure of lung cancer therapy and the poor prognosis of
lung cancer. However, the mechanisms of metastasis
have not yet been fully elucidated.
MicroRNAs (miRNAs) are small, non-coding RNA
molecules that negatively regulate gene expression,
mainly through direct interaction with the 3’-untranslated
region (3’-UTR) of corresponding target messenger RNAs
(mRNA) [3]. After binding to target mRNAs, miRNAs
form a complex with target mRNAs and decrease the levelshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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by suppressing translation of the target mRNA [4]. It has
been reported that miRNAs can post-transcriptionally regu-
late 30% of human genes, thereby suggesting that miRNAs
may have pivotal roles in physiological and pathological
processes, including human carcinogenesis [5]. Over the
past 10 years, evidence has emerged that miRNAs were
crucial for the initiation, promotion, and progression of hu-
man cancers. A large number of miRNAs have recently
been implicated in cancer metastasis [6]. For example, miR-
155, miR-222, miR-210, miR-107, and miR-10a have a role
in pancreatic cancer [7-9], miR-148a, miR-23a, and miR-
193a in hepatocellular carcinoma [10-12], and miR-200,
miR-218 in gastric cancer [13,14]. Furthermore, miR-133b,
miR-143 and miR-32 in colorectal cancer [15-17]. However,
only a few miRNAs known involved in NSCLC metastasis
have been reported. A better understanding of the changes
in miRNA expression during NSCLC invasion may lead to
a better understanding of NSCLC development, as well as
to possible improvements in the diagnosis and treatment of
advanced NSCLC.
Previously, we established a highly invasive (SPC-A-1sci)
cell subline and a weakly invasive (SPC-A-1) cell subline by
in vivo selection in NOD/SCID mice [18]. We compared
the global miRNA profiles of SPC-A-1sci and SPC-A-1 cell,
and revealed low expression levels of miR-200c had influ-
ence on the invasion and migration ability of NSCLC cell
lines [19]. In this work, miR-200c has been investigated in
much greater detail, because miR-200c has been reported
to be correlated with EMT [20], and SPC-A-1sci cells
display phenotypic changes consistent with EMT [18]. Re-
cently, miR-200c has been reported in several tumors, in-
cluding breast cancer, lung cancer, esophageal cancers,
colorectal cancer, and pancreatic cancer [21-25]. These
findings indicate that miR-200c may function importantly
in human carcinogenesis. However, for miR-200c, the po-
tential roles and related target genes in NSCLC metastasis
are still not well elucidated.
Results
MiR-200c suppresses the migration and invasion of
NSCLC cells in vitro
To clarify the significance of miR-200c in human NSCLC
metastasis, we investigated the expression of miR-200c
in7 human NSCLC cell lines by qRT-PCR. The expression
levels of miR-200c were higher in the SPC-A-1, XL-2,
H460, and H358 cell lines than in the A549, H1299, and
SPC-A-1sci cell lines (Figure 1A). The migration and inva-
sion ability of 7 human NSCLC cell lines were compared
by using transwell assays with or without matrigel. All cell
lines higher-expressing miR-200c (SPC-A-1, XL-2, H460,
and H358) showed fewer cells than the cell lines with
low levels of miR-200c (A549, H1299, and SPC-A-1sci)
(Figure 1B,C).On the basis of the results showing the suppression of
miR-200c expression in high metastatic NSCLC cells,
loss- and gain-of-function studies of miR-200c were con-
ducted using a transient transfection strategy with miR-200c
mimics or inhibitors (Additional file 1: Figure S1A and B).
The invasion and migration ability of A549, H1299 and
SPC-A-1sci cells transfected with miR-200c mimics were
significantly decreased when compared with the invasion
and migration ability of the control cells (Figure 1D-F). On
the other hand, silencing of miR-200c by transfecting the
miR-200c inhibitor into the SPC-A-1 cells increased cell
invasion and migration ability (Figure 1G). Therefore,
the expression of miR-200c may affect the invasion and
migration of human NSCLC cells in vitro.
Over-expression of miR-200c impairs the formation of
metastases of NSCLC cells in vivo
We asked whether expression of miR-200c would also
affect metastatic behaviors in vivo. To address this
possibility, SPC-A-1 transfected with miR-200c inhibitor
or miR-control inhibitor lentiviral vector, SPC-A-1sci
with miR-200c or miR-control lentiviral vector were
inoculated into nude mice through the lateral tail vein
(Additional file 2: Figure S2). After twelve weeks, lung
metastasis was apparent in mice injected SPC-A-1 trans-
fected with miR-200c inhibitor lentiviral vector compared
with negative control cells. In stark contast, few metastatic
tumors were detected in mice injected SPC-A-1sci with
miR-200c lentiviral vector compared with control group
for eight weeks (Figure 2A). Similar trends are observable
in histologic analysis (Figure 2B). The numbers of lung
metastasis nodules were significantly increased in miR-200c
inhibitor lentiviral vector group, decreased in miR-200c
lentiviral vector group, respectively, when compared with
control group (Figure 2C).
Moreover, SPC-A-1sci cells stably expressing miR-control
or miR-200c lentiviral vector were injected subcutaneously
into the right upper flank region of five-week-old NOD/
SCID mice. After twelve weeks, the results showed that
increased expression of miR-200c impaired NSCLC cells
the formation of metastases (Figure 2). These results were
similar through the lateral tail vein. Taken together, our
results suggest that miR-200c is a negative regulator for
NSCLC metastasis.
MiR-200c expression modulates the epithelial-mesenchymal
transition (EMT)
A typical morphological change of SPC-A-1sci, SPC-A-1
was noted after treatment with miR-200c lentiviral vector
or miR-200c inhibitor lentiviral vector. Compared with the
control cells, the results showed that a significant decrease
in spindle-shaped cells was paralleled by an increase in
rounded cells in miR-200c-transduced SPC-A-1sci cells.
In contrast, more rounded cells became spindle-shaped in
Figure 1 Correlation analysis of miR-200c expression and invasion capacity. (A) Levels of miR-200c expression in 7 human NSCLC cell lines
were measured by quantitative real-time RT-PCR. U6 was used for normalization. (B and C) The invasion and migration ability of 7 human NSCLC
lines was determined by using the matrigel migration and invasion assay. (D-G) Transwell migration and invasion assays for SPC-A-1sci, H1299,
and A549 cells were performed after transduction with by miR-200c mimics or miR-controls, and SPC-A-1 cells were performed after transduction
with miR-200c inhibitor or miR-control. The results are representative of at least three independent experiments. Statistical analysis was performed
using Student’s t-test. Error bars represent S.E.M. *P < 0.05; **P < 0.01; ***P < 0.001.
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vector (Figure 3A). E-cadherin and N-cadherin protein
expression levels were measured by Western blotting. Up-
regulated miR-200c expression levels enhanced E-cadherin
protein expression, but inhibited N-cadherin protein
expression, and that down-regulated miR-200c expres-
sion levels inhibited E-cadherin protein expression, but
enhanced N-cadherin protein expression (Figure 3B).
In addition, we examined the E-cadherin, N-cadherin,
Phalloidin expression by confocal immunofluorescence.
Similar results were also found in immunofluorescence,
whereas the changes of E-cadherin and N-cadherin by
immunostaining were not as sharp as that observed by
western blot. E-cadherin and N-cadherin were increased
and decreased, respectively, in miR-200c-transduced
SPC-A-1sci cells. In contrast, E-cadherin and N-cadherin
were decreased and increased, respectively, in miR-
200c-inhibitor-treated SPC-A-1 cells (Figure 3C). These
observations reveal that miR-200c can inhibit the EMT
of NSCLC cells.
Evidence has emerged that miR-200c directly targets
one of the major EMT transcription factor ZEB1 and in
turn suppresses EMT. We analyzed the expression of ZEB1
by qRT-PCR and western blotting, the results showed that
a corresponding reduction in mRNA and protein levelswere also detectable for ZEB1 in response to miR-200c up-
regulation in SPC-A-1sci cells. Conversely, increased mRNA
and protein expressions for ZEB1 were also demonstrated
following transfection with the miR-200c inhibitor in
SPC-A-1 cells (Additional file 3: Figure S3A and B). We next
analyzed the expressions of E-cadherin, and N-cadherin,
when the expression of ZEB1 was knocked down by siRNA
in SPC-A-1sci cells. The results showed ZEB1 suppressed
EMT in NSCLC (Additional file 3: Figure S3C). Taken to-
gether, these results showed that miR-200c could suppress
EMT by directly targeting ZEB1. The results were consist-
ent with other reports.
USP25 is a direct target of miR-200c during NSCLC metastasis
To determine how the low level of miR-200c expression
contributes to the invasion and metastasis of NSCLC
cells, we examined the global mRNA expression profile
of SPC-A-1sci and SPC-A-1 cells. We searched for the
potential regulatory targets of miR-200c by considering
the up-regulated genes from the gene chip and using pre-
diction tools, including miRNAMap, miRanda, and PicTar
(Figure 4A). Five potential target genes were selected
for validation and further analysis: USP25, SMURF2, ID2,
PLK2, PKIA. The down-regulation of only three of these
genes: USP25, PKIA, and SMURF2, following ectopic
Figure 2 Overexpression of miR-200c suppress NSCLC cells metastases in vivo. (A and B) Representative gross photo of a mouse lung and
the images of histological inspection of a mouse lung for the presence of microscopic lesions twelve weeks after tail vein injection (xenograft)
with SPC-A-1 cells stably expressing the miR-200c inhibitor or miR-control inhibitor lentiviral vector, and eight weeks after tail vein injection
(xenograft), twelve weeks after subcutaneous injection (subcutaneous) with SPC-A-1sci cells stably expressing the miR-200c or miR-control
lentiviral vector. (C) Quantification of lung microscopic nodules in the lungs of each group. Statistical analysis was performed using Student’s
t-test. Error bars represent S.E.M. *P < 0.05; **P < 0.01; ***P < 0.001.
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by real-time PCR analysis (Figure 4B and Additional file 4:
Figure S4A).
To determine if miR-200c directly targets the 3’UTRs
of USP25, PKIA, and SMURF2, we constructed vectors
containing the full-length wild-type or mutant 3’-UTR
of USP25, PKIA, SMURF2 directly fused to the down-
stream of the firefly luciferase gene (Figure 4C and
Additional file 4: Figure S4B). The wild-type or mutant
vector was co-transfected into HEK-293T cells with
miR-200c mimics or miR-control. The transfection ef-
ficiency was normalized by cotransfection with Renillareporter vector. The results shown miR-200c significantly
decreased the relative luciferase activity of wild-type
USP25 and SMURF2 3’-UTR, whereas the reduction of
the luciferase activity with mutant USP25, SMURF2 of
3’-UTR was not as sharp as that observed in the wild-type
counterpart. The reduction of the luciferase activity with
wild-type or mutant PKIA of 3’-UTR was not observed
(Figure 4D and Additional file 4: Figure S4C, D). A corre-
sponding reduction at the protein levels was also detect-
able by Western blot for USP25 and SMURF2 in response
to miR-200c up-regulation. Conversely, increased mRNA
and protein expressions for USP25 and SMURF2 were
Figure 3 miR-200c regulated the epithelial-mesenchymal transition (EMT). (A) SPC-A-1 cells were transfected with miR-control inhibitor or
miR-200c inhibitor lentiviral vector, and SPC-A-1sci cells were transfected with the miR-control or miR-200c lentiviral vector. Light microscope pictures
were taken after transfection (100x magnification). (B) The protein levels of E-cadherin (epithelial marker) and N-cadherin (mesenchymal marker) were
determined by western blot analyses after transfection with miR-control inhibitor or miR-200c inhibitor lentiviral vector, and SPC-A-1sci cells
were transfected with the miR-control or miR-200c lentiviral vector. β-actin served as an internal control. (C) Immunofluorescence staining of
E-cadherin, N-cadherin, and Phalloidin, after transfection with miR-control inhibitor or miR-200c inhibitor lentiviral vector, and SPC-A-1sci cells
were transfected with the miR-control or miR-200c lentiviral vector. The red, green signal represents the staining of the indicated proteins, and
the blue signal represents the nuclear DNA staining by DAPI. Magnification, 600×. The results are representative of at least three independent
experiments.
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miR-200c inhibitor in SPC-A-1 cells (Figure 4E and
Additional file 4: Figure S4E).
Next, we investigated which, if any, miR-200c direct tar-
geted mediate the capacity for cellular invasion. USP25 and
SMURF2 seemed appealing: USP25 is involved in negative
regulation of IL-17-mediated signaling and inflammation
by interacting with TRAF5 and TRAF6, and regulates
TLR4-dependent innate immune responses through
deubiquitination of the adaptor protein TRAF3 [26,27].
But few studies have been performed to determine the
significance of USP25 in tumor metastasis; SMURF2 is
known to suppress tumor angiogenesis and metastasis
[28], However, others reported that SMURF2 promoted
metastasis in breast cancer cells [29]. Given their describedroles, USP25 and SMURF2 seemed plausible candidates
to shape the miR-200c-mediated invasion and migration
of NSCLC cells. To determine whether any of them were
critical mediators of miR-200c’s role in cellular invasion,
we silenced SMURF2 using RNA interference (RNAi) in
SPC-A-1sci cell lines (Additional file 5: Figure S5A, B). The
results showed that downregulating SMURF2 enhanced
invasion (Additional file 5: Figure S5C, D).
USP25 has a critical role in miR-200c-mediated invasion
and migration of NSCLC cells
To determine whether USP25 was critical mediators of
miR-200c’s role in cellular invasion, we confirmed that the
knock-down of USP25 expression levels by siRNA in A549,
H1299 and SPC-A-1sci cells, siRNA remarkably reduced
Figure 4 USP25 expression is downregulated by miR-200c directly targeting of the 3’-UTR of USP25. (A) USP25 was found for the
potential regulatory targets of miR-200c by considering the up-regulated genes from the gene chip and using prediction tools, including
miRNAMap, miRanda, and PicTar. (B) The USP25 mRNA levels were determined by real-time PCR analysis after transfection with the miR-200c
mimics or negative control in SPC-A-1sci cells or after transfection with the miR-200c inhibitor or negative control in SPC-A-1cells. β-actin served
as an internal control. (C) The putative miR-200c binding site in the USP25 3’-UTR. (D) Luciferase activity assays for luciferase reporters with
wild-type or mutant USP25 3’-UTR were performed after co-transfected with miR-200c mimics or miR-control in 293T cells. The luciferase activity
of each sample was normalized to Renilla luciferase activity. (E) USP25 protein levels were determined by western blot analyses after transfection
with the miR-200c mimics or negative control in SPC-A-1sci cells or after transfection with the miR-200c inhibitor or negative control in SPC-A-1
cells. β-actin served as an internal control. The results are representative of at least three independent experiments. Statistical analysis was
performed using Student’s t-test. Error bars represent S.E.M. *P < 0.05; **P < 0.01; ***P < 0.001.
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down of USP25 by siRNA in A549, H1299, and SPC-A-1sci
cells inhibited cell migration and invasion in vitro,
which fell to levels similar to those observed after trans-
fection with the miR-200c mimics (Figure 5B-D). To
demonstrate the contribution of USP25 to the bio-
logical function of miR-200c, we examined whether
the co-transfection of si-USP25 had an effect on miR-
200c-inhibitor-induced cell migration and invasion in
SPC-A-1 cells (Figure 5E).
These observations suggest that miR-200c directly
suppresses USP25-mediated cell invasion. Moreover, over-
expression of miR-200c in USP25 knockdown SPC-A-1sci
cells were conducted using a transient transfection strategy
with miR-200c mimics (Additional file 6: Figure S6A).
The invasion and migration ability of USP25 knock-
down SPC-A-1sci cells transfected with miR-200c
mimics were significantly decreased when compared
with the invasion and migration ability of the control
cells (Additional file 6: Figure S6B).Decreased expression of USP25 inhibits human NSCLC
cell metastasis in vivo
To further explore the role of USP25 on tumor metastasis
in vivo,SPC-A-1sci cells with stably knocked-down USP25
expression (sh-USP25) and the negative control (sh-NC)
were inoculated into the tail veins of nude mice or into the
right upper flank region of NOD/SCID mice. Lung metas-
tasis was apparent in mice injected with SPC-A-1sci-sh-NC
cells. In contrast, few metastatic tumors were detected
in mice injected with SPC-A-1sci-sh-USP25 cells. The
histological examination of lung tissue indicated that the
number of lung metastatic nodules significantly decreased
in mice inoculated with shRNA-USP25 cells compared
to shRNA-NC cells (Figure 6). In short, our results in-
dicate that decreased expression of USP25 inhibits human
NSCLC cell metastasis in vivo.
miR-200c, and USP25 expression in NSCLC
Based on the similar results of experiments using
NSCLC cell lines and xenograft models, it appears that
Figure 5 USP25 functions as a metastasis promoter and its molecular mechanism. (A) The protein levels of USP25 were determined by
western blot analyses after transfection with si-USP25 or a negative control in SPC-A-1sci, A549, H1299 cells, β-actin served as an internal control.
(B-D) Transwell migration and invasion assays for SPC-A-1sci, A549, and H1299 cells were performed after transfection with si-USP25 or a negative
control. (E) Transwell migration and invasion assays for SPC-A-1-miR-control and SPC-A-1-anti-miR-200c cells were performed after transduction
with si-USP25 or a negative control. The results are representative of at least three independent experiments. Statistical analysis was performed
using Student’s t-test. Error bars represent S.E.M. *P < 0.05; **P < 0.01; ***P < 0.001.
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NSCLC invasion and metastasis through USP25. To de-
termine the potential clinicopathological implications of
altered miR-200c expression, we investigated the expression
levels of miR-200c in 73 NSCLC tissues and non-tumor
tissues by qRT–PCR. The results verified that the miR-
200c expression level in NSCLC tissues was lower than
that in non-tumor tissues (Figure 7A). Statistically signifi-
cant associations between the miR-200c expression level
and clinical stage and between the miR-200c expression
level and NSCLC metastasis were observed in this study.
The expression of miR-200c was lower in NSCLC patients
with lymphatic metastasis, distant metastasis than in those
without lymphatic metastasis (Figure 7B). Further analysis
showed that miR-200c levels were significantly lower in
the NSCLC patients with clinical advanced stage (3/4AB)
than early-stage (1/2AB) (Figure 7C), but did not correl-
ate with tumor size (Figure 7D). These data supported
decreased miR-200c expression in NSCLC was associated
with advanced clinical stage, lymph node metastasis.
Next, we investigated the expression levels of USP25 in
these patients, the results revealed higher mRNA levels of
USP25 were found in NSCLC tissues than non-tumor tis-
sues (Figure 7E), correlated with distant metastasis, and
clinical advanced stage (Figure 7F,G). In addition, the level
of USP25 had a significant inverse correlation with tumorsize (Figure 7H). Lastly, we investigated whether miR-
200c level was associated with the mRNA levels of USP25
in these patients. The result revealed tumors with a low
level of miR-200c tended to express high levels of USP25,
whereas, tumors with a high level of miR-200c tended to
express low levels of USP25 (Figure 7I). Hence, it appears
that miR-200c negatively regulates tumor metastasis in
NSCLC patients by targeting USP25.
USP25 protein levels in NSCLC are associated with advanced
clinical stage, histological grade, and lymph node metastasis
To further examine the clinical relevance of this finding,
we detected USP25 protein levels expression in human
NSCLC tissues (n = 256) and matched adjacent normal
tissues by Immunohistochemical staining. Correlations be-
tween the USP25 expression level and clinicopathologic
characteristics of NSCLC are summarized in Table 1 and
Figure 8. The high USP25 level correlated positively with
poor tumor differentiation (P = 0.0002). The expression of
USP25 was higher in the NSCLC patients with clinical ad-
vanced stage than early-stage (P = 0.0062). Further analysis
showed that USP25 levels were significantly higher in
NSCLC patients with lymphatic metastasis than in those
without lymphatic metastasis (P < 0.0001). In addition,
USP25 levels were higher in primary cancers than in
the adjacent controls (P < 0.0001), whereas USP25 levels
Figure 6 The promoter roles of USP25 on lung metastasis in vivo. (A, B) Representative gross photo of a mouse lung and the images of
histological inspection of a mouse lung for the presence of microscopic lesions eight weeks after tail vein injection (xenograft) or subcutaneous
injection (subcutaneous) with SPC-A-1sci cells stably expressing the sh-USP25 or sh-NC. (C) Quantification of lung microscopic nodules in the
lungs of each group. Statistical analysis was performed using Student’s t-test. Error bars represent S.E.M. *P < 0.05; **P < 0.01; ***P < 0.001.
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to clinicopathologic features, we found that high protein
levels of USP25 positively correlated with clinical stage,
histological grade, and lymphatic metastasis in NSCLC
patients, indicating that USP25 plays an important role
in NSCLC progression.
Discussion
In recent years, many studies have shown that the ex-
pression of miRNAs is aberrant in human cancer [30].
Identification of tumor-associated miRNAs and their tar-
get genes is critical for understanding the roles of miR-
NAs in tumorigenesis and may be important for novel
therapeutic targets [31].In our previous work, we isolated invasive and non-
invasive cell subpopulations from human NSCLC SPC-A-1
cell lines by in vivo selection in NOD/SCID mice [18]. We
identified 117 novel metastasis-related miRNAs in NSCLC
based on a well-established metastasis cell model [19].
The finding that miR-200c was downregulated in
metastatic SPC-A-1sci cells was intriguing, because de-
creased miR-200c levels have been reported in several
other types of tumor [21,23-25], thus indicating that
decreased miR-200c may be a common event in the
tumorigenesis. Other reports showed serum miR-200c
associated with poor prognosis in patients with lung
cancer [32]. In H1299 cells miR-200c targets multiple
non-small cell lung cancer prognostic markers DLC1,
Figure 7 Clinical validation of miR-200c and USP25. (A,E) Real-time PCR analysis to quantify the levels of miR-200c, USP25 in NSCLC tissues
and non-tumor tissues. (B,F) Real-time PCR analysis to quantify the levels of miR-200c, USP25 in NSCLC tissues with lymphatic metastasis (Nx),
distant metastasis (T) or without metastasis (N0). (C,G) Real-time PCR analysis to quantify the levels of miR-200c, USP25 in the NSCLC patients with
clinical early-stage (1/2AB) or advanced-stage (3/4AB). (D,H) Real-time PCR analysis to quantify the levels of miR-200c, USP25 in the NSCLC
patients with tumor size <3 cm or >3 cm. (I) Real-time PCR analysis the levels of USP25 in patients with low and high miR-200c expression levels.
Statistical analysis was performed using Student’s t-test. Error bars represent S.E.M. *P < 0.05; **P < 0.01; ***P < 0.001.
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role in NSCLC metastasis remains largely elusive.
We focused on the effect of miR-200c on NSCLC
metastasis and showed that miR-200c acted as a tumor
suppressor during NSCLC metastasis. The expression
of miR-200c was negatively correlated with the invasion
and migration of NSCLC cell lines in vitro. Moreover, our
results suggest that decreased miR-200c levels promoted,
increased miR-200c levels inhibited NSCLC cell migration
and invasion in vitro and metastasis in vivo. The activity
of miR-200c in relation to EMT- associated phenotypes
has been extensively studied [34]. In the current study, we
also found miR-200c was associated with EMT. Together,
these findings suggest that miR-200c functions as a key
mediator of metastasis in NSCLC.
As part of our research on how the miR-200c affects
NSCLC metastasis, several bioinformatics tools for screen-
ing putative miRNA target genes were used, including
miRNAMap, PicTar and miRanda and up-regulated genes
in gene chip. We demonstrated that USP25 was a critical
downstream target of miR-200c. To test this assumption,
we investigated whether miR-200c inhibited USP25 mRNA
and protein levels, then found that up-regulation of
miR-200c led to a significant decrease in USP25 mRNA
and protein levels, thereby suggested that USP25 was afunctional target of miR-200c. Lastly, the dual-luciferase
reporter assays suggested that USP25 was one of the
functional downstream targets of miR-200c. The effect
of USP25 on tumor metastasis has not been studied. In
the current study, we found that knockdown of USP25
expression reduced NSCLC cell metastasis similar to
that of the restoration of miR-200c.
To determine the potential clinicopathological impli-
cations of altered miR-200c expression, we investigated
the expression levels of miR-200c in 73 NSCLC tissues
and non-tumor tissues by qRT–PCR. The results showed
that the miR-200c expression level in NSCLC tissues was
lower than that in non-tumor tissues, and negatively asso-
ciated with advanced clinical stage, lymph node metasta-
sis. Next, we investigated the expression levels of USP25
in these patients, the results revealed higher mRNA levels
of USP25 were found in NSCLC tissues than non-tumor
tissues, correlated with distant metastasis, and advancing
stage. Lastly, we found a low level of miR-200c tended to
express high levels of USP25, whereas tumors with a high
level of miR-200c tended to express low levels of USP25.
In addition, there was a significant association between
USP25 protein levels positively correlated with clinical
stage, histological grade, and lymphatic metastasis by
Immunohistochemical staining in 256 NSCLC patients.
Table 1 Correlation between secreted USP25 levels in
NSCLC patients and their clinicopathologic characteristics
Clinical
pathology
USP25 levels (IHC) N P value
–+ + + + + +-+ + + +
Gender
Male 54(29.2) 49(26.5) 82(44.3) 185
0.0066*
Female 10(14.1) 18(25.4) 43(60.5) 71
Age
≦63 30(21.9) 34(24.8) 73(53.3) 137
0.0985
>63 34(28.6) 34(28.6) 51(42.8) 119
Tumor size (cm)
<3.5 19(20.6) 16(17.4) 57(62) 92
0.012*3.5-6 25(25) 32(32) 43(43) 100
>6 20(31.3) 19(29.7) 25(39) 64
Histological grade
Ι/Ι-Π 15(36.6) 13(31.7) 13(31.7) 41
0.0002*Π 33(27) 38(31.1) 51(41.9) 122
Π-Ш/Ш 16(17.2) 16(17.2) 61(65.6) 93
Clinical Stage
1AB 26(41.3) 12(19) 25(39.7) 63
0.0062*2AB 23(20.4) 35(31) 55(48.7) 113
3AB/4 15(18.7) 20(25) 45(56.3) 80
Lymph node status
Metastasis 24(15.4) 42(26.9) 90(57.7) 156
<0.0001*
No metastasis 40(40) 25(25) 35(35) 100
Carcinoma
Primary 64(25) 67(26.2) 125(48.9) 256
<0.0001*
Adjacent 132(51.6) 123(48) 1(0.4) 256
P value represents the probability from a chi-square test for tissue USP25
levels between variable subgroups, *P < 0.05.
Figure 8 Representative IHC images of the expression of USP25 betw
measured by the percentage of positive cells with the following staining inte
50–74% scored “3”; and more than 74% scored “4”.
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effect of miR-200c was at least partly mediated through
a decrease in USP25 expression.
USP25 is a member of ubiquitinating-specific proteases
(USPs) family, which contain two short, conserved
fragments (lysine and histidine boxes) that contain Cys,
His and Asn residues, which form a catalytic triad that
can remove ubiquitin molecules from large proteins [35].
Ubiquitination is a post-translational protein modification
referring to the attachment of the small protein ubiquitin
to a lysine residue of a target protein. This modification is
more versatile than other post-translational modifications
because several ubiquitin molecules can be added to the
first, creating chains of ubiquitin on the target proteins
that modify the signal [36]. The ubiquitin proteasome
system regulates all processes that are involved in car-
cinogenesis, among them invasion and metastasis, EMT,
the process that endows neoplastic cells with invasive
and metastatic potential, is intimately interwoven with
other neoplastic processes, being served by several com-
mon pathways, several of which are regulated by the
ubiquitin proteasome system [37]. USP28 is a key regula-
tor of the DNA damage checkpoint, high expression levels
of USP28 are found in colon and breast carcinomas, and
stabilization of MYC by USP28 is essential for tumour-cell
proliferation [38]. USP22 are found significantly associ-
ated with progression and unfavorable clinical outcome
in esophageal squamous cell carcinoma, NSCLC [39,40].
USP4 is regulated by AKT phosphorylation and directly
deubiquitylates TGF-β type I receptor [41].
Recently, USP25 was significantly frequent mutation in
HCC [42], and was involved in negative regulation of IL-
17-mediated signaling and inflammation by interacting
with TRAF5 and TRAF6,and regulates TLR4-dependent
innate immune responses through deubiquitination of theeen lung cancer and adjacent noncancerous tissues. Scoring was
nsities: less than 5% scored “0”; 5–24% scored “1”; 25–49% scored “2”;
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TRAF family have been identified (TRAF1-7), and play
an important role in a variety of signaling pathways.
TRAF6, a unique TRAF family member, possesses a unique
receptor-binding specificity, which is important for its
crucial role as the signaling mediator for not only the TNF
receptor superfamily but also the IL-1R/Toll-like receptor
superfamily [43,44]. The downstream signals activated by
TRAF6 mainly include NF-κB and AP-1, while NF-κB and
AP-1 play an important role in the transcription and ex-
pression of numerous genes (including carcinogenesis,
invasion and metastasis etc.) in organism [45].
Conclusions
In this study, we provided first-time evidence that when
significantly down-regulated miR-200c promoted NSCLC
cell invasion and migration, at least partly through the
induction of USP25, which was a potential metastasis
promoter in NSCLC. These findings have implications
for new mechanisms of miR-200c mediated regulation of
lung cancer, and suggest that miR-200c may be a potential
therapeutic target for human NSCLC.
Methods
Cell culture
The human lung cell lines A549, H1299, SPC-A-1sci,
SPC-A-1, XL-2, H460, H358, and HEK-293T were main-
tained in our laboratory. XL-2 cells were established from
the abdomen of a NSCLC patient. All cell lines were
routinely maintained in DMEM medium (HyClone) sup-
plemented with 10% fetal bovine serum (Biowest, South
America Origin), 100U/ml penicillin sodium, and 100mg/ml
streptomycin sulfate at 37°C in a humidified air atmosphere
containing 5% CO2. Cells were used when they were in
the logarithmic growth phase.
Cell transfections
The miR-200c mimics, and miR-200c inhibitors that
were used in this study were synthesized by Ribobio
(Guangzhou, China). Genepharma synthesized the USP25
siRNA. The following sequences were as follows: USP25
siRNA sense: 5’-GGGAGUACUUGAAGGUAAATT-3’;
anti-sense: 5’-UUUACCUUCAAGUACUCCCTT-3’; neg-
tive control sense: 5’-UUCUCCGAACGUGUCACGUTT-
3’; anti-sense: 5’-ACGUGACACGUUCGGAGAATT-3’.
Oligonucleotide transfection was performed with Lipofecta-
mine 2000 reagents according to the manufacturer’s instruc-
tions (Invitrogen, CA). For migration, invasion, Western
blottingassays andreal-timequantitativeRT-PCR(qRT-PCR),
cellswere collected48hafter transfection.
In vitro migration and invasion assays
Cell migration and invasion assays were performed in
a 24-well plate with 8-mm pore size chamber inserts(Corning, New York, NY, USA). For migration assays,
5 × 104 cells expressing miR mimic, miR inhibitor, miR
control and negative control were placed into the
upper chamber per well with the non-coated mem-
brane. For invasion assays, 1 × 105 cells expressing miR
mimic, miR inhibitor, miR control and negative control
were placed into the upper chamber per well with the
Matrigel-coated membrane, which was diluted with
serum-free culture medium. In both assays, cells were
suspended in 200 ml of DMEM without fetal bovine
serum when they were seeded into the upper chamber.
In the lower chamber, 800 ml of DMEM supplemented
with 10% fetal bovine serum was added.After incubation
for some hours at 37°C and 5% CO2, the membrane in-
serts were removed from the plate, and non-invading cells
were removed from the upper surface of the membrane.
Cells that moved to the bottom surface of the chamber
were fixed with 100% methanol for 20 min and stained
with 0.1% crystal violet for 30 min. Then, the cells were
imaged and counted in at least 10 random fields using a
CKX41 inverted microscope (Olympus,Tokyo, Japan). The
assays were conducted three independent times.
Establishing stable NSCLC cells
The miR-200c lentiviral vector, miR-200c inhibitor len-
tiviral vector and miR-control lentiviral vector were
synthesized by Genepharma. The sh-USP25 lentiviral
vector and sh-control lentiviral vector were synthesized by
Openbiosystems (USA).
Real-time quantitative RT-PCR (qRT-PCR)
The expression of miRNAs was measured using the
TaqMan stem-loop RT-PCR method from Applied
Biosystems (Foster City, CA, USA). Approximately 10 ng
of total RNA was reverse-transcribed according to the
MicroRNA Reverse Transcription kit and a specific stem-
loop primer according to the manufacturer’s instructions
(Applied Biosystems, Foster City, CA). Samples were
normalized to RNU6B. SYBR green RT-PCR (TaKaRa)
was performed to detect USP25. The sequences are as
follows: USP25 Sense: 5’-CGGTCCCAAACGATTCCC-
3’; Antisense: 5’–CTCCCTGTTCTGTTGTGCT-3’. All
RT-PCR experiments were performed on the GeneAmp®
PCR System 9700 (Applied Biosystems, Foster City, CA).
All RT-PCR assays were carried out using a 7300
Real-Time PCR System with SDS RQ Study software
(Applied Biosystems).
In vivo assays for metastasis
For the experimental metastasis mouse xenograft model,
SPC-A-1 cells transfected with miR-control,miR-200c in-
hibitor lentiviral vector, SPC-A-1sci cells stably expressing
miR-control, miR-200c lentiviral vector, knocked-down
USP25 expression, the negative control were inoculated
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mice(N = 12). For spontaneous metastasis mouse model,
SPC-A-1sci cells stably expressing miR-control, miR-
200c lentiviral vector, knocked-down USP25 expression,
the negative control were injected subcutaneously into
the right upper flank region of five-week-old NOD/
SCID mice(N = 10). The animals were maintained under
specific pathogen free (SPF) conditions. The mice were
manipulated and housed according to protocols ap-
proved by the Shanghai Medical Experimental Animal
Care Commission. Each tumor cell subline was injected
2 × 106 per mouse. After some weeks, the mice were
sacrificed, and the lungs were harvested at necropsy and
fixed in 10% neutral PB-buffered formalin (pH 7.4). The
fixed samples were then embedded in paraffin, and five
non-sequential serial sections were obtained per animal.
The sections were stained with H&E and analyzed for
the presence of metastases.
Western blot
Cell proteins were extracted and separated in SDS-PAGE
gels, and transferred to nitrocellulose filter membranes
(Millipore, USA). Western blot analyses were performed
according to standard procedures. Western blot loading
control was β-actin (Sigma-Aldrich, 1:30000). The following
antibodies were used: anti-USP25 (Abcam, 1:1000), anti-
E-cadherin (CST, 1:1000), anti-N-cadherin (CST, 1:1000).
Immunofluorescence and immunohistochemical analysis
Cells were plated and grown on glass slides for 18 ~ 20
hours and fixed with 4% paraformaldehyde. The slides were
then blocked and incubated with the following primary
antibodies: Anti-E-cadherin was obtained from Santa Cruz
(1:25), Anti-N-cadherin was obtained from Santa Cruz
(1:25). Finally, the slides were incubated with fluorescence
conjugated secondary antibody (Sigma 1:50) and viewed
with a Fluoview FV1000 microscope (Olympus, Japan).
Luciferase assay
Total cDNA from HUVEC cells was used to amplify the




of the 3’-UTR of the USP25-mutant by PCR was per-
formed, using the forward primer: 5’–CCTGTTGGTGAT
ATACTTTGCTTTTATCTTTTC-3'; and the reverse
primer:5’–CAAAGTATATCACCAACAGGAAGGTGGC
AAAAG-3'. The XhoI and NotI restriction enzyme sites
were used. HEK293T cells were plated into 96-well plates
at 50% confluence 24 h before transfection. The pmiR
report-control vector and Luc-USP25, Luc-USP25-mu,
or Luc-control vectors were co-transfected into HEK293T
cells using Lipofectamine 2000. Lysates were prepared at48 h post-transfection. Luciferase activity was measured
using a Dual-Luciferase Reporter System (Promega).
Human NSCLC tissues
Patient samples in this study were obtained following
informed consent, according to an established protocol
approved by the Ethic Committee of Shanghai Jiao-Tong
University School. The data did not contain any informa-
tion that may lead to the identification of the patients.
73 NSCLC tissues and matched adjacent noncancerous
tissues for RNA extraction were provided by Shanghai chest
hospital. Of these 73 NSCLC tissues, 16 were squamous cell
carcinomas and 57 were non squamous cell carcinomas.
Matched pairs of NSCLC tissues and matched adjacent non-
cancerous tissues were used for the construction of a tissue
microarray (Shanghai Biochip Co., Ltd. Shanghai, China)
as previously described [46]. There were 256 NSCLC
tissues and matched adjacent noncancerous tissues in
the tissue microarray. Of these 256 NSCLC tissues, 134
were squamous cell carcinomas and 122 were non squa-
mous cell carcinomas. Immunohistochemical staining was
performed to detect the expression of USP25 in NSCLC
tissues and matched non-cancerous tissues. The primary
antibody against USP25 was obtained from Abcam (1:50).
Scoring was measured by the percentage of positive
cells with the following staining intensities: less than
5% scored “–”; 5–24% scored “+”; 25–49% scored “++”;
50–74% scored “+++”; and more than 74% scored “++++”.
Statistical analysis
The results are presented as mean ± SD. Comparisons of
quantitative data were analyzed by Student’s t-test between
two groups (two-tailed; P < 0.05 was considered significant).
Fisher’s exact test was used to compare qualitative variables.
Analysis was performed with SAS 9.0 for Windows.
Additional files
Additional file 1: Figure S1. Real-time PCR demonstrated the relative
miRNA levels. (A) The miR-200c was determined by real-time PCR analysis
after SPC-A-1sci, A549, H1299 cells transfected with miR-control or
miR-200c mimics. (B) The miR-200c, miR-200a, miR-200b, miR-141, miR-429
were determined by real-time PCR analysis after SPC-A-1 transfected with
miR-control inhibitor or miR-200c inhibitor .U6 served as an internal control.
Additional file 2: Figure S2. Real-time PCR demonstrated miR-200c
levels.The miR-200c was determined by real-time PCR analysis after SPC-A-1
transfected with miR-control inhibitor or miR-200c inhibitor lentiviral vector,
and SPC-A-1sci cells were transfected with the miR-control or miR-200c
lentiviral vector. U6 served as an internal control.
Additional file 3: Figure S3. ZEB1 regulated the epithelial-mesenchymal
transition (EMT). (A,B) ZEB1 mRNA and protein levels were determined by
real-time PCR and western blot analyses after transfection with the miR-200c
mimics or negative control in SPC-A-1sci cells or after transfection with the
miR-200c inhibitor or negative control in SPC-A-1cells. β-actin served as an
internal control. (C) E-cadherin, N-cadherin, ZEB1 protein levels were
determined by western blot analyses after transfection with si-ZEB1 or a
negative control in SPC-A-1sci cells. β-actin served as an internal control.
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http://www.molecular-cancer.com/content/13/1/166Additional file 4: Figure S4. Other target genes of miR-200c. (A) The
ID2, SMURF2, PKIA, and PLK2 mRNA levels were determined by real-time
PCR analysis after transfection with the miR-200c mimics or negative
control in SPC-A-1sci cells or after transfection with the miR-200c inhibitor
or negative control in SPC-A-1cells. β-actin served as an internal control.
(B) The putative miR-200c binding site in the SMURF2, PKIA 3’-UTR. (C,D)
Luciferase activity assays for luciferase reporters with wild-type or mutant
SMURF2, PKIA 3’-UTR were performed after co-transfected with miR-200c
mimics or miR-control in 293T cells. The luciferase activity of each sample
was normalized to Renilla luciferase activity. (E) The SMURF2 protein
levels were determined by western blot analyses after transfection with
the miR-200c mimics or negative control in SPC-A-1sci cells or after
transfection with the miR-200c inhibitor or negative control in
SPC-A-1cells. β-actin served as an internal control.
Ad∩ditional file 5: Figure S5. Downregulating SMURF2 enhanced
human NSCLC cell invasion in vitro. (A,B) SMURF2 mRNA and protein
levels were determined by real-time PCR and western blot analyses after
transfection with si-SMURF2 or a negative control in SPC-A-1sci cells.
β-actin served as an internal control. (C,D) Transwell migration and
invasion assays for SPC-A-1sci cells were performed (100x magnification)
after transfection with si-SMURF2 or a negative control. The results are
representative of at least three independent experiments. Statistical analysis
was performed using Student’st-test. Error bars represent S.E.M. *P<0.05;
**P<0.01; ***P<0.001.
Additional file 6: Figure S6. Over-expression of miR-200c in USP25
knockdown SPC-A-1sci cells decreased the invasion and migration ability.
(A) USP25 protein levels were determined by western blot analyses after
over-expression of miR-200c in USP25 knockdown SPC-A-1sci cells. β-actin
served as an internal control. (B) Transwell migration and invasion assays
were performed after over-expression of miR-200c in USP25 knockdown
SPC-A-1sci cells. The results are representative of at least three independent
experiments. Statistical analysis was performed using Student’st-test. Error
bars represent S.E.M. * P<0.05; ** P<0.01; ***P<0.001.
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